

# Regence

Medical Policy Manual

Surgery, Policy No. 132

## ***Cryosurgical Ablation of Miscellaneous Solid Tumors Outside of the Liver***

**Effective:** February 1, 2024

**Next Review:** November 2024

**Last Review:** December 2023

### **IMPORTANT REMINDER**

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

### **DESCRIPTION**

Cryoablation kills cells by freezing the tissue using a coolant that is circulated via a probe inserted into the tumor.

### **MEDICAL POLICY CRITERIA**

**Note:** This policy does not address liver tumors (primary or metastatic). See Cross References.

- I. Cryosurgical ablation may be considered **medically necessary** for the treatment of any of the following indications:
  - A. Malignant dermatologic tumors
  - B. Uveal melanoma
  - C. Kidney tumors
  - D. Prostate tumors
  - E. Cervical intraepithelial neoplasia

- F. Lung cancer when either of the following criteria is met:
1. For non-small cell lung cancer when the patient has early-stage (Stage I, and selected node negative Stage IIA) non-small cell lung cancer; or
  2. The patient requires palliation for a central airway obstructing lesion.
- II. Cryosurgical ablation is considered **investigational** as a treatment for all solid tumors not meeting Criterion I, including desmoid tumors and malignant or benign tumors of the breast (including fibroadenoma), pancreas, and bone; and for metastases outside of the liver or prostate.

*NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.*

## LIST OF INFORMATION NEEDED FOR REVIEW

It is critical that the list of information below is submitted for review to determine if the policy criteria are met. If any of these items are not submitted, it could impact our review and decision outcome.

- History and Physical
- Treatment plan including treatment area.

## CROSS REFERENCES

1. [Radioembolization, Transarterial Embolization \(TAE\), and Transarterial Chemoembolization \(TACE\)](#), Medicine, Policy No. 140
2. [Radiofrequency Ablation \(RFA\) of Tumors Other than Liver](#), Surgery, Policy No. 92
3. [Magnetic Resonance \(MR\) Guided Focused Ultrasound \(MRgFUS\) and High Intensity Focused Ultrasound \(HIFU\) Ablation, Surgery](#), Policy No. 139
4. [Microwave Tumor Ablation](#), Surgery, Policy No. 189
5. [Ablation of Primary and Metastatic Liver Tumors](#), Surgery, Policy No. 204
6. [Focal Laser Ablation of Prostate Cancer](#), Surgery, Policy No. 222

## BACKGROUND

Cryosurgical ablation (also called cryosurgery, cryotherapy, or cryoablation) kills cells (cancerous and normal) by freezing target tissues, most often by inserting a probe into the tumor through which coolant is circulated. Cryosurgery may be performed as an open surgical technique or as a closed procedure under laparoscopic or ultrasound guidance.

The goals of cryosurgery may include the following:

- Destruction or shrinkage of tumor tissue
- Controlling local tumor growth and preventing recurrence
- Palliating symptoms
- Extending survival duration for patients with certain tumors.

Potential complications associated with cryosurgery in any organ include the following:

- Hypothermic damage to normal tissue adjacent to the tumor (e.g., nerve damage)
- Structural damage along the probe track
- Secondary tumors if cancerous cells are seeded during probe removal.

## REGULATORY STATUS

There are several cryoablation devices cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use in open, minimally invasive or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, proctology, thoracic surgery and ear, nose and throat. Examples include:

- Cryocare® Surgical System by Endocare;
- CryoGen Cryosurgical System by Cryosurgical, Inc.;
- CryoHit® by Galil Medical;
- IceRod® CX, IcePearl® 2.1 CX and IceFORCE® 2.1 CX Cryoablation Needles by Galil Medical;
- IceSense3™, ProSense™, and MultiSense Systems (IceCure Medical);
- SeedNet™ System by Galil Medical;
- Visica® System by Sanarus Medical;
- Visual-ICE® Cryoablation System by Galil;
- ERBECRYO 2® Cryosurgical Unit, ERBE USA Incorporated

## EVIDENCE SUMMARY

In order to understand the impact of cryosurgical ablation on local or distant tumor recurrence and disease-free and overall survival in patients with solid tumors, randomized trials are needed that compare this technique with current standard treatments. The standard treatment for most solid tumors is surgical resection. For unresectable solid tumors, alternatives to resection depend on the tumor type and location, and may include thermal ablation, percutaneous ethanol injection, chemoembolization, chemotherapy, and radiation therapy.

Despite the weaknesses in the published clinical evidence, cryosurgical ablation has become a recognized standard of care for tumors of the kidney, liver (addressed in Ablation of Primary and Metastatic Liver Tumors, Surgery, Policy No. 204), prostate, and carefully selected patients with tumors of the lung.<sup>[1-51]</sup>

The following literature appraisal focuses on the investigational indications noted in medical policy criteria above.

### BREAST TUMORS

The standard treatment for breast cancer is surgical excision by lumpectomy or mastectomy, with or without adjuvant radiation therapy, chemotherapy, and/or hormone therapy. Fibroadenomas, benign tumors of the breast, generally do not require treatment. If treated, they are typically surgically excised.

### Systematic Reviews

One systematic review, by Zhao (2010), was found that included cryoablation along with other minimally-invasive thermal ablation techniques (i.e., radiofrequency, microwave, cryoablation and high-intensity focused ultrasound) for treatment of early-stage breast cancer.<sup>[52]</sup> Zhao reported that studies on cryoablation for breast cancer were primarily limited to pilot and feasibility studies conducted in the research setting. A wide range of 36-83% was reported for complete ablation of tumors. The authors concluded that, while promising, large randomized

controlled trials are needed to further evaluate patient selection criteria, techniques to ensure complete tumor ablation, and long-term outcomes compared with surgical excision of breast tumors.

### **Randomized Controlled Trials**

There are no prospective, randomized controlled trials comparing survival and recurrence rates following cryoablation of breast tumors with surgical excision or, for unresectable tumors, with nonoperative therapies.

### **Nonrandomized Studies**

The remaining nonrandomized evidence does not permit reliable conclusions concerning the impact of cryosurgical ablation on breast cancer survival or recurrence due to a number of methodological limitations, including: heterogeneous or unreported patient selection criteria, the use of varied cryoablation techniques, nonrandomized allocation of treatment, lack of an appropriate surgical excision control group for comparison, small subject population, and limited data on long-term outcomes.<sup>[53-66]</sup>

## **PULMONARY TUMORS**

### **Systematic Reviews**

Lee (2011) conducted a systematic review of endoscopic cryoablation of lung and bronchial tumors.<sup>[67]</sup> Included in the review were 15 case studies and one comparative observational study. Cryoablation was performed for inoperable, advanced lung and bronchial cancers in most studies. Some studies included patients with comorbid conditions and poor general health who would not be considered surgical candidates. Complications occurred in 11.1% of patients (10 studies) and consisted of hemorrhage, mediastinal emphysema, atrial fibrillation, and dyspnea. Within 30 days of the procedure, death from hemoptysis and respiratory failure, considered to be most likely related to disease progression, occurred in 7.1% of patients. Improvements in pulmonary function and clinical symptoms occurred in studies reporting these outcomes. One published review reported the outcomes of 15 case series and one comparative observational study for endoscopic cryotherapy of endobronchial tumors. Most studies were for inoperable, advanced lung and bronchial cancers. A critical analysis of the studies was not provided. However, the authors noted the significant limitations in the available evidence due to lack of control groups, lack of random treatment allocation, and heterogeneity in study methodologies, participants' characteristics (e.g., comorbid conditions, general health, cancer grade), treatment protocols, operative techniques, and outcome measures. Complications occurred in 11.1% of patients from ten studies and consisted of hemorrhage, mediastinal emphysema, atrial fibrillation, and dyspnea. Within 30 days of the procedure, death from hemoptysis and respiratory failure, considered to be most likely related to disease progression, occurred in 7.1% of patients. Improvements in pulmonary function and clinical symptoms occurred in studies reporting these outcomes. Because the studies in the review did not include control groups or compare outcomes of cryosurgery to alternative strategies for managing similar patients, no conclusions can be made on the net health outcomes of cryosurgery for lung cancer.

### **Randomized Controlled Trials**

One preliminary randomized trial studied 36 female patients with NSCLC who also had epidermal growth factor receptor gene mutations.<sup>[68]</sup> All patients received six months treatment

with molecular target therapy gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor. Patients were randomized to either an experimental group and underwent cryoablation prior to receiving gefitinib, or to a control group in which cryoablation was not performed. At one-year follow-up, the survival rate in the cryoablation group was significantly higher than that of the control group. The findings of this preliminary study suggest that cryoablation may improve the effects of gefitinib in this patient population. Additional larger, long-term randomized trials are needed to validate these findings.

## **Nonrandomized Studies**

The Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE) study assessed the safety and local recurrence-free survival after cryoablation for treatment of pulmonary metastases. Callstrom (2020) published this multicenter, prospective, single-arm, phase 2 study in 128 patients with 224 lung metastases  $\leq 3.5$  cm.<sup>[69]</sup> Median tumor size was 1.0 cm. Local recurrence-free response was 85.1% at 12 months and 77.2% at 24 months. Secondary local recurrence-free response after retreatment with cryoablation for recurrent tumors was 91.1% at 12 months and 84.4% at 24 months. Overall survival at 12 and 24 months was 97.6% and 86.6%, respectively.

The ECLIPSE trial is prospective, multicenter trial of cryoablation for metastatic disease in the lungs, interim results at one-year follow-up were published in 2015.<sup>[70]</sup> The trial enrolled 40 patients with 60 metastatic lung lesions who were treated with cryoablation and had at least 12 months of follow-up. Outcomes included survival, local tumor control, quality of life, and complications. Local tumor control was achieved in 94.2% (49/52) of treated lesions, and one-year OS was 97.5% (39/40). There were no significant changes in quality of life over the 12-month study. The most common adverse event was pneumothorax requiring chest tube insertion in 18.8% (9/48 procedures). Five-year results of the trial were published by de Baère (2021), which reported disease-specific survival rates of 74.8% at three years and 55.3% at five years.<sup>[70]</sup> Five-year overall survival was 46.7% and there was no significant difference in quality-of-life measures.

## **BONE TUMORS**

### **Systematic Reviews**

Khanmohammadi (2023) published a systematic review of cryoablation for the palliation of painful bone metastases.<sup>[71]</sup> The review included 15 studies (n=376): ten case series and five prospective interventional studies. Of these, six were scored as “good,” six as “fair,” and three as “poor” according to the NIH Study Quality Assessment Tools. A total of 436 metastatic lesions were treated, mostly in the spine, pelvic bone, and ribs. All of the studies reported a statistically significant reduction in pain between one day and six months following the procedure.

A systematic review by Sagoo (2022) assessed percutaneous cryoablation of spinal metastases.<sup>[72]</sup> Eight studies, seven of which were retrospective, were included in the review, with a total of 148 patients and 187 treated lesions (3 cervical, 74 thoracic, 37 lumbar, and 17 sacrococcygeal). At one-month follow-up, the pooled mean difference in pain scores (1-10 scale) was 5.03 (95% confidence interval [CI] 4.24 to 5.82). Reported tumor control rates varied from 60% to 100% and complications were reported in 12 patients, three of which were grade III-V.

Lindquester (2020) published a systematic review evaluating percutaneous thermal ablation technologies for osteoid osteoma, which included 36 case-series (total n=1,798).<sup>[73]</sup> While the authors stated that the studies were evaluated for quality, the results of such an evaluation were not included in the publication. An overall success rate of 91.9% was reported, which included both technical and clinical success of the procedure as well as freedom from recurrence during follow-up, however median length of follow-up in these studies was not reported. The overall complication rate was 2.5% (95% CI 1.9% to 3.3%). No significant differences were found between radiofrequency and cryoablation, but only three of the 36 studies included cryoablation; most (32 studies) were for radiofrequency ablation.

## **Nonrandomized Studies**

Cazzato (2022) published a review of 74 patients with spinal metastases who underwent cryoablation treatment at two academic medical centers.<sup>[74]</sup> Of these, 21 patients underwent treatment for curative purposes while 53 were treated for palliative purposes. Cryoablation was associated with a reduction in pain among those who presented with painful lesions. Local tumor control was achieved in 21 patients undergoing cryoablation with curative intent (mean follow-up of 25.9 ± 21.2 months).

Jennings (2021) reported on a multicenter, single-arm prospective study of 66 patients with metastatic bone disease who were treated with cryoablation, all of whom were not candidates for or had not benefited from standard therapy.<sup>[75]</sup> The primary endpoint was the change in pain score from baseline to week eight and patients were followed for 24 weeks. The mean decrease in pain score from baseline to week eight was 2.61 points (95% CI 3.45 to 1.78). Pain scores decreased further after the primary endpoint and reached clinically meaningful levels (more than a two-point decrease) after week eight. This study was limited by its lack of a comparator, potential for selection bias, and lack of blinding combined with subjective outcome measures.

Callstrom (2013) reported on 61 patients treated with cryoablation for pain from 69 tumors (size 1 to 11 cm) metastatic to the bone. Before treatment, patients rated their pain with a 4+ on a 1-to-10 scale using the Brief Pain Inventory, with a mean score of 7.1 for worst pain in a 24-hour period. The mean pain score gradually decreased after cryoablation to 1.4 (p<0.001) at 24 weeks for worst pain in a 24-hour period. A major complication of osteomyelitis was experienced by one (2%) patient.

Meller (2008) retrospectively analyzed a single-center experience with 440 bone tumor cryosurgery procedures performed between 1988 and 2002, two-thirds of them for primary benign-aggressive and low-grade malignant lesions, and one-third for primary high-grade and metastatic bone tumors.<sup>[76]</sup> At a median follow-up of seven years (range 3 to 18 years), the overall recurrence rate was 8%. Based on their data, the authors suggested that the ideal case for cryosurgery is a young adult with involvement of long bone, a benign-aggressive or low-grade malignant bone tumor, a good cavity with greater than 75%-thick surrounding walls, no or minimal soft-tissue component, and at least ±1 cm of subchondral bone left near a joint surface after curettage and burr drilling.

## **OTHER TUMORS**

Cryoablation for the treatment of other solid tumors has not been well-studied.

## **Systematic Reviews**

Keane (2014) reported on a systematic review of ablation therapies, including cryoablation, for locally advanced pancreatic cancer.<sup>[77]</sup> The review noted studies have demonstrated ablative therapies, including cryoablation, are feasible but larger studies are needed. No conclusions could be made on whether ablation resulted in better oncologic outcomes than best supportive care.

Tao (2012) reported on a systematic review of cryoablation for pancreatic cancer.<sup>[78]</sup> The authors identified 29 studies from the literature search and included five of these studies in the review. The five studies were all case series and considered to be of low quality. Adverse events, when mentioned in the studies, included delayed gastric emptying (0% to 40.9% in three studies), pancreatic leak (0% to 6.8% in four studies), biliary leak (0% to 6.8% in three studies), and one instance of upper gastrointestinal hemorrhage. Pain relief was reported in three studies and ranged from 66.7% to 100%. Median survival times reported in three studies ranged from 13.4 to 16 months. One-year total survival rates reported in two studies were 57.5% and 63.6%.

### **Nonrandomized Studies**

The remaining published literature is limited to case series and retrospective reviews.<sup>[79-89]</sup> As discussed above, these studies do not permit reliable conclusions concerning the impact of cryoablation on health outcomes.

## **PRACTICE GUIDELINE SUMMARY**

Clinical practice guidelines from U.S. professional associations consistently list cryoablation as a treatment option for uveal melanoma, certain NSCLC tumors, and for tumors of the kidney or prostate.<sup>[90-96]</sup>

No clinical practice guidelines or position statements based on research from U.S. professional societies were identified that specifically recommend cryoablation for the treatment of solid tumors other than those listed above, though some refer more generally to ablation procedures.<sup>[97-98]</sup>

## **SUMMARY**

Cryosurgical ablation has become a recognized standard of care in the management of tumors of the skin, kidney and prostate, uveal melanoma, cervical intraepithelial neoplasia, and carefully selected patients with lung tumors. Therefore, this technique may be considered medically necessary in the treatment of these tumors when criteria are met.

There is not enough research to show that cryosurgical ablation can improve health outcomes for patients with solid tumors that do not meet policy criteria, including malignant or benign tumors of the breast (including fibroadenoma), pancreas, and bone; and for metastases outside of the liver or prostate. Therefore, cryosurgical ablation for these indications is considered investigational.

## **REFERENCES**

1. Kunkle DA,Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. *Cancer*. 2008;113(10):2671-80. PMID: 18816624
2. Long L,Park S. Differences in patterns of care: reablation and nephrectomy rates after needle ablative therapy for renal masses stratified by medical specialty. *J Endourol*. 2009;23(3):421-6. PMID: 19260799
3. Laguna MP, Beemster P, Kumar V, et al. Perioperative morbidity of laparoscopic cryoablation of small renal masses with ultrathin probes: a European multicentre experience. *Eur Urol*. 2009;56(2):355-61. PMID: 19467771
4. Gill IS, Remer EM, Hasan WA, et al. Renal cryoablation: outcome at 3 years. *J Urol*. 2005;173(6):1903-7. PMID: 15879772
5. Niu R, Yan TD, Zhu JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. *Ann Surg Oncol*. 2007;14(7):2078-87. PMID: 17473951
6. Seifert JK, Springer A, Baier P, et al. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. *Int J Colorectal Dis*. 2005;20(6):507-20. PMID: 15973545
7. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. *Ann Surg Oncol*. 2007;14(3):1161-9. PMID: 17195903
8. Joosten J, Jager G, Oyen W, et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. *Eur J Surg Oncol*. 2005;31(10):1152-9. PMID: 16126363
9. Kornprat P, Jarnagin WR, DeMatteo RP, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. *Arch Surg*. 2007;142(11):1087-92. PMID: 18025338
10. Si T, Guo Z,Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. *J Immunother*. 2009;32(1):86-91. PMID: 19307997
11. Onik G, Vaughan D, Lotenfoe R, et al. The "male lumpectomy": focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. *Urol Oncol*. 2008;26(5):500-5. PMID: 18774463
12. Langenhuijsen JF, Broers EM,Vergunst H. Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. *Eur Urol*. 2009;55(1):76-86. PMID: 18789572
13. Eisenberg ML,Shinohara K. Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. *Urology*. 2008;72(6):1315-8. PMID: 18597824
14. Ng CK, Moussa M, Downey DB, et al. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. *J Urol*. 2007;178(4 Pt 1):1253-7; discussion 57. PMID: 17698104
15. Van Poppel H, Becker F, Cadeddu JA, et al. Treatment of localised renal cell carcinoma. *Eur Urol*. 2011;60(4):662-72. PMID: 21726933
16. Chou R, Dana T, Bougatsos C, et al. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation. Rockville (MD). 2011. PMID: 22171386
17. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. *BJU international*. 2012;109 Suppl 1:22-9. PMID: 22239226



18. Williams SB, Lei Y, Nguyen PL, et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer. *BJU international*. 2012;110(2 Pt 2):E92-8. PMID: 22192688
19. Mouraviev V, Spiess PE, Jones JS. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. *Eur Urol*. 2012;61(6):1204-11. PMID: 22421081
20. Nabi G, Cleves A, Shelley M. Surgical management of localised renal cell carcinoma. *Cochrane Database Syst Rev*. 2010(3):CD006579. PMID: 20238346
21. O'Malley RL, Berger AD, Kanofsky JA, et al. A matched-cohort comparison of laparoscopic cryoablation and laparoscopic partial nephrectomy for treating renal masses. *BJU international*. 2007;99(2):395-8. PMID: 17092288
22. Long CJ, Kutikov A, Canter DJ, et al. Percutaneous vs surgical cryoablation of the small renal mass: is efficacy compromised? *BJU international*. 2011;107(9):1376-80. PMID: 21062399
23. Klatte T, Grubmuller B, Waldert M, et al. Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. *Eur Urol*. 2011;60(3):435-43. PMID: 21616582
24. El Dib R, Touma NJ, Kapoor A. Cryoablation vs radiofrequency ablation for the treatment of renal cell carcinoma: a meta-analysis of case series studies. *BJU international*. 2012;110(4):510-6. PMID: 22304329
25. Matin SF, Ahrar K. Nephron-sparing probe ablative therapy: long-term outcomes. *Current opinion in urology*. 2008;18(2):150-6. PMID: 18303535
26. Rodriguez R, Cizman Z, Hong K, et al. Prospective analysis of the safety and efficacy of percutaneous cryoablation for pT1NxMx biopsy-proven renal cell carcinoma. *Cardiovascular and interventional radiology*. 2011;34(3):573-8. PMID: 20628879
27. Shelley M, Wilt TJ, Coles B, et al. Cryotherapy for localised prostate cancer. *Cochrane Database Syst Rev*. 2007(3):CD005010. PMID: 17636783
28. Chin JL, Ng CK, Touma NJ, et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. *Prostate cancer and prostatic diseases*. 2008;11(1):40-5. PMID: 17579613
29. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. *Cancer*. 2010;116(2):323-30. PMID: 19937954
30. Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. *Cancer*. 2009;115(20):4695-704. PMID: 19691092
31. Huang YZ, Zhou SC, Zhou H, et al. Radiofrequency Ablation versus Cryosurgery Ablation for Hepatocellular Carcinoma: A Meta-Analysis. *Hepato-gastroenterology*. 2013;60(127). PMID: 23321123
32. Yang Y, Wang C, Lu Y, et al. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. *Journal of hepato-biliary-pancreatic sciences*. 2012;19(6):674-84. PMID: 22187145
33. Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. *American journal of clinical oncology*. 2012;35(5):439-45. PMID: 21654315
34. Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. *Eur Urol*. 2013;64(1):1-7. PMID: 22840351

35. Valerio M, Ahmed HU, Emberton M, et al. The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. *Eur Urol*. 2013. PMID: 23769825
36. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? *Diagn Interv Radiol*. 2013;19(6):501-7. PMID: 24084196
37. Cordeiro ER, Barwari K, Anastasiadis A, et al. Laparoscopic cryotherapy for small renal masses: Current State. *Archivos espanoles de urologia*. 2013;66(1):41-53. PMID: 23406799
38. Kapoor A, Touma NJ, Dib RE. Review of the efficacy and safety of cryoablation for the treatment of small renal masses. *Can Urol Assoc J*. 2013;7:E38-44. PMID: 23401737
39. Durand M, Barret E, Galiano M, et al. Focal Cryoablation: A Treatment Option For Unilateral Low-Risk Prostate Cancer. *BJU international*. 2013. PMID: 24053685
40. Punnen S, Cooperberg MR, D'Amico AV, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. *Eur Urol*. 2013;64(6):905-15. PMID: 23721958
41. Tang K, Yao W, Li H, et al. Laparoscopic renal cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal masses: a systematic review and meta-analysis of comparative studies. *Journal of laparoendoscopic & advanced surgical techniques Part A*. 2014;24(6):403-10. PMID: 24914926
42. Klatter T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *J Urol*. 2014;191(5):1209-17. PMID: 24231845
43. Korpan NN. Hepatic cryosurgery for liver metastases. Long-term follow-up. *Annals of surgery*. 1997;225(2):193-201. PMID: 9065296
44. Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. *Hepatology*. 2015;61(5):1579-90. PMID: 25284802
45. Xiong T, Turner RM, Wei Y, et al. Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. *BMJ Open*. 2014;4:e004285. PMID: 24833678
46. Zargar H, Atwell TD, Cadeddu JA, et al. Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. *Eur Urol*. 2015. PMID: 25819723
47. Wolff RF, Ryder S, Bossi A, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. *Eur J Cancer*. 2015;51(16):2345-67. PMID: 26254809
48. Caputo PA, Ramirez D, Zargar H, et al. Laparoscopic Cryoablation for Renal Cell Carcinoma: 100-Month Oncologic Outcomes. *J Urol*. 2015;194(4):892-6. PMID: 25912493
49. Ratko TA, Vats V, Brock J, et al. Local Nonsurgical Therapies for Stage I and Symptomatic Obstructive Non-Small-Cell Lung Cancer. *AHRQ Comparative Effectiveness Reviews*. 2013. PMID: 23865091
50. Pessoa RR, Autorino R, Laguna MP, et al. Laparoscopic Versus Percutaneous Cryoablation of Small Renal Mass: Systematic Review and Cumulative Analysis of Comparative Studies. *Clinical genitourinary cancer*. 2017;15(5):513-19 e5. PMID: 28442227

51. Moore W, Talati R, Bhattacharji P, et al. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. *J Vasc Interv Radiol*. 2015;26(3):312-9. PMID: 25735518
52. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol*. 2010;36(12):1149-55. PMID: 20889281
53. Pfliederer SO, Freesmeyer MG, Marx C, et al. Cryotherapy of breast cancer under ultrasound guidance: initial results and limitations. *Eur Radiol*. 2002;12(12):3009-14. PMID: 12439583
54. Suzuki Y. Cryosurgical treatment of advanced breast cancer and cryoimmunological responses. *Skin Cancer*. 1995;10:19-26. PMID: No PMID Entry
55. Morin J, Traore A, Dionne G, et al. Magnetic resonance-guided percutaneous cryosurgery of breast carcinoma: technique and early clinical results. *Can J Surg*. 2004;47(5):347-51. PMID: 15540687
56. Littrup PJ, Jallad B, Chandiwala-Mody P, et al. Cryotherapy for breast cancer: a feasibility study without excision. *J Vasc Interv Radiol*. 2009;20(10):1329-41. PMID: 19800542
57. Sabel MS, Kaufman CS, Whitworth P, et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. *Ann Surg Oncol*. 2004;11(5):542-9. PMID: 15123465
58. Kaufman CS, Bachman B, Littrup PJ, et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas. *Am J Surg*. 2002;184(5):394-400. PMID: 12433600
59. Kaufman CS, Littrup PJ, Freman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas: 12-month followup. *J Am Coll Surg*. 2004;198(6):914-23. PMID: 15194073
60. Kaufman CS, Bachman B, Littrup PJ, et al. Cryoablation treatment of benign breast lesions with 12-month follow-up. *Am J Surg*. 2004;188(4):340-8. PMID: 15474424
61. Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast fibroadenomas. *Radiology*. 2005;234(1):63-72. PMID: 15550369
62. Kaufman CS, Littrup PJ, Freeman-Gibb LA, et al. Office-based cryoablation of breast fibroadenomas with long-term follow-up. *Breast J*. 2005;11(5):344-50. PMID: 16174156
63. Nurko J, Mabry CD, Whitworth P, et al. Interim results from the FibroAdenoma Cryoablation Treatment Registry. *Am J Surg*. 2005;190(4):647-51; discussion 51-2. PMID: 16164941
64. Manenti G, Perretta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. *Eur Radiol*. 2011;21(11):2344-53. PMID: 21681574
65. Pusztaszeri M, Vlastos G, Kinkel K, et al. Histopathological study of breast cancer and normal breast tissue after magnetic resonance-guided cryotherapy ablation. *Cryobiology*. 2007;55(1):44-51. PMID: 17604016
66. Simmons RM, Ballman KV, Cox C, et al. A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. *Ann Surg Oncol*. 2016;23(8):2438-45. PMID: 27221361
67. Lee SH, Choi WJ, Sung SW, et al. Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. *Korean J Intern Med*. 2011;26(2):137-44. PMID: 21716589
68. Gu XY, Jiang Z, Fang W. Cryoablation Combined with Molecular Target Therapy Improves the Curative Effect in Patients with Advanced Non-small Cell Lung Cancer. *J Int Med Res*. 2011;39(5):1736-43. PMID: 22117974
69. Callstrom MR, Woodrum DA, Nichols FC, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). *Journal of*

- thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2020;15(7):1200-09. PMID: 32151777
70. de Baere T, Tselikas L, Woodrum D, et al. Evaluating Cryoablation of Metastatic Lung Tumors in Patients--Safety and Efficacy: The ECLIPSE Trial--Interim Analysis at 1 Year. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2015;10(10):1468-74. PMID: 26230972
  71. Khanmohammadi S, Noroozi A, Yekaninejad MS, et al. Cryoablation for the Palliation of Painful Bone Metastasis: A Systematic Review. *Cardiovascular and interventional radiology*. 2023;46(11):1469-82. PMID: 36631660
  72. Sagoo NS, Haider AS, Ozair A, et al. Percutaneous image-guided cryoablation of spinal metastases: A systematic review. *J Clin Neurosci*. 2022;96:120-26. PMID: 34840092
  73. Lindquister WS, Crowley J, Hawkins CM. Percutaneous thermal ablation for treatment of osteoid osteoma: a systematic review and analysis. *Skeletal Radiol*. 2020;49(9):1403-11. PMID: 32151777
  74. Cazzato RL, Jennings JW, Autrusseau PA, et al. Percutaneous image-guided cryoablation of spinal metastases: over 10-year experience in two academic centers. *Eur Radiol*. 2022;32(6):4137-46. PMID: 35028752
  75. Jennings JW, Prologo JD, Garnon J, et al. Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. *Radiol Imaging Cancer*. 2021;3(2):e200101. PMID: 33817650
  76. Meller I, Weinbroum A, Bickels J, et al. Fifteen years of bone tumor cryosurgery: a single-center experience of 440 procedures and long-term follow-up. *Eur J Surg Oncol*. 2008;34(8):921-7. PMID: 18158228
  77. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. *World J Gastroenterol*. 2014;20(9):2267-78. PMID: 24605026
  78. Tao Z, Tang Y, Li B, et al. Safety and effectiveness of cryosurgery on advanced pancreatic cancer: a systematic review. *Pancreas*. 2012;41(5):809-11. PMID: 22695092
  79. Kovach SJ, Hendrickson RJ, Cappadona CR, et al. Cryoablation of unresectable pancreatic cancer. *Surgery*. 2002;131(4):463-4. PMID: 11935137
  80. Xu KC, Niu LZ, Hu YZ, et al. A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. *World J Gastroenterol*. 2008;14(10):1603-11. PMID: 18330956
  81. Li J, Chen X, Yang H, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. *Postgrad Med J*. 2011;87(1024):89-95. PMID: 21131612
  82. Thacker PG, Callstrom MR, Curry TB, et al. Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablation. *AJR Am J Roentgenol*. 2011;197(2):510-5. PMID: 21785102
  83. Masala S, Guglielmi G, Petrella MC, et al. Percutaneous ablative treatment of metastatic bone tumours: visual analogue scale scores in a short-term series. *Singapore Med J*. 2011;52(3):182-9. PMID: 21451927
  84. Welch BT, Atwell TD, Nichols DA, et al. Percutaneous image-guided adrenal cryoablation: procedural considerations and technical success. *Radiology*. 2011;258(1):301-7. PMID: 20971772
  85. Yamauchi Y, Izumi Y, Kawamura M, et al. Percutaneous cryoablation of pulmonary metastases from colorectal cancer. *PLoS One*. 2011;6(11):e27086. PMID: 22096520

86. Callstrom MR, Dupuy DE, Solomon SB, et al. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. *Cancer*. 2013;119(5):1033-41. PMID: 23065947
87. Poplack SP, Levine GM, Henry L, et al. A Pilot Study of Ultrasound-Guided Cryoablation of Invasive Ductal Carcinomas up to 15 mm With MRI Follow-Up and Subsequent Surgical Resection. *AJR Am J Roentgenol*. 2015;204(5):1100-8. PMID: 25905948
88. Saltiel S, Bize PE, Goetti P, et al. Cryoablation of Extra-Abdominal Desmoid Tumors: A Single-Center Experience with Literature Review. *Diagnostics (Basel, Switzerland)*. 2020;10(8). PMID: 32759783
89. Zheng Z, Zhao Y, An Y, et al. Efficacy of argon-helium cryoablation and its effects on immune function of patients with neck malignant tumors. *Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery*. 2020. PMID: 32920994
90. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Prostate Cancer. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Prostate Cancer [cited 12/6/2023]. 'Available from:' [http://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf).
91. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Kidney Cancer. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Kidney Cancer [cited 12/6/2023]. 'Available from:' [http://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf).
92. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. *J Urol*. 2008;180:1993-2004. PMID: 18817934
93. Sun F, Oyesanmi O, Fontanarosa J, et al. 2014. PMID: 25610935
94. Campbell SC, Novick AC, Belldgrun A, et al. Guideline for management of the clinical T1 renal mass. *J Urol*. 2009;182(4):1271-9. PMID: 19683266
95. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Non-small cell lung cancer. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Non-small cell lung cancer [cited 12/6/2023]. 'Available from:' [http://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf).
96. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Uveal Melanoma. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Uveal Melanoma [cited 12/6/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/uveal\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uveal_blocks.pdf).
97. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Bone Cancer. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Bone Cancer [cited 12/6/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/bone.pdf](https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf).
98. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Soft Tissue Sarcoma. Secondary National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology™. Soft Tissue Sarcoma [cited 12/6/2023]. 'Available from:' [https://www.nccn.org/professionals/physician\\_gls/pdf/sarcoma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf).

## CODES

Codes	Number	Description
CPT	0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral
	17260- 17286	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement)
	19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma
	20983	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation
	31641	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with destruction of tumor or relief of stenosis by any method other than excision (eg, laser therapy, cryotherapy)
	32994	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation
	50250	Ablation, open, 1 or more renal mass lesion(s), cryosurgical, including intraoperative ultrasound guidance and monitoring, if performed
	50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring, when performed
	50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy
	55873	Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)
	57511	Cautery of cervix; cryocautery, initial or repeat
HCPCS	None	

**Date of Origin:** March 2004